NICE calls for more research on ELISA tests for Crohn’s diseaseBMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i1019 (Published 18 February 2016) Cite this as: BMJ 2016;352:i1019
- Jacqui Wise
Enzyme linked immunosorbent assay (ELISA) kits show real promise in guiding treatment for people with Crohn’s disease, but the National Institute for Health and Care Excellence (NICE) warns that evidence is insufficient to recommend their routine use in the NHS.1
Tumour necrosis factor alpha (TNF-α) inhibitors, such as infliximab and adalimumab, help to stop inflammatory responses in the gut that are characteristic of Crohn’s disease. Although TNF-α inhibitors can help many people with Crohn’s, some do …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial